Invitrogen, BayBio Sign Partnership Agreement

Business Wire, Nov 11, 2008

CARLSBAD, Calif. & SOUTH SAN FRANCISCO, Calif. -- Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, announced today its partnership with BayBio, a leading voice for the life sciences industry in Northern California.

"BayBio is a vital voice for California's life sciences industry and is an effective leader in the state's capital. This partnership enables us to support BayBio's mission to create growth in areas such as regenerative cell therapy, and help to expedite scientific discoveries using our most innovative tools," said Bernd Brust, Invitrogen's Senior Vice President of Worldwide Sales and Marketing.

The BayBio Partner Program recognizes the life sciences industry's leaders and brings unique opportunities to the employees of BayBio Partners, including meetings with California's elected officials, policy makers and other opinion leaders from across the globe.

"Invitrogen's growing influence in the life sciences community can have a profound impact in supporting this important industry in the State of California," said Matthew M. Gardner, President and CEO of BayBio. "This important relationship creates new resources that allow the life sciences industry to reach greater heights in the Golden State by providing more cures, treatments and products for the world's population."

About BayBio

BayBio is an independent, non-profit 501(c)(6) trade association serving the life science industry in Northern California. The staff and services of BayBio are paid primarily through memberships, sponsorships, and event registration fees. BayBio provides these services through representatives in South San Francisco and through coalition partners in Washington, DC. Through advocacy, membership services, programs and more, BayBio brings the world's greatest life science community to your fingertips. For more information, visit www.baybio.org.

About Invitrogen

Invitrogen Corporation (NASDAQ:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, stem cells, cell therapy and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California, and conducts business in more than 70 countries around the world. The company employs approximately 4,700 scientists and other professionals and had revenues of approximately $1.3 billion in 2007. For more information, visit www.invitrogen.com.